The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | High-dose melphalan as a preparative regimen for autoHSCT in HL and NHL
Guillermo José Ruiz-Argüelles, MD, FRCP, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico, summarizes the results of a Latin American study evaluating high-dose melphalan prior to autologous hematopoietic stem cell transplantation (autoHSCT) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), highlighting the benefits of this preparative regimen. This strategy allows to deliver autoHSCT without freezing cells and is cheaper than other preparative regimens. Overall, the study demonstrated that high-dose melphalan was non-inferior to BEAM and mini-BEAM preparatory regimens. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
